J. David Enloe, Jr., CEO of Ajinomoto Althea was awarded Most Admired CEO in 2017 by the San Diego Business Journal. This award recognized David for leading Althea through a phase of significant growth while fostering several technical innovation and organizational development initiatives. Under Enloe’s leadership, Althea achieved its highest revenue in its 18 year history in 2016 and has grown its revenues by 25 percent year-over-year for the last 3 years, when he came to San Diego to take over Althea soon after its acquisition by Ajinomoto, a large Japanese firm.
This award acknowledges David for guiding Althea to achieve a four-fold increase in the number of manufactured commercially approved drug products and for the expansion from one to eight countries that have authorized commercial use of Althea’s products. In addition to this strong growth, David has launched several new initiatives to foster further growth for Althea over the upcoming years. He drove Althea’s entry into the rapidly growing oncology field of antibody drug conjugate (ADC) manufacturing which will enable the company to partner with more clients globally.
Enloe was recognized for spearheading negotiations of the first multimillion dollar license of Althea’s proprietary Crystalomics formulation technology, monetizing many of the Crystalomics patents, and launching a new company technology and service offering. Althea now has Crystalomics contracts with six of the top ten BioPharma companies in the world.